Latest news with #ZAVA
Daily Record
4 days ago
- Health
- Daily Record
Doctors issue alert for Mounjaro users as popular summer drink could derail weight loss
People using Mounjaro for shedding pounds may need to reconsider that holiday tipple this summer While alcohol doesn't directly interfere with Mounjaro medication, your favourite sugary beverage could wreck your weight loss progress and might ruin your break before it truly begins. Doctors at ZAVA warned that these summer staples can cause your blood sugar levels to crash and dehydrate you. This effect can be particularly severe for those on Mounjaro, potentially leading to lightheadedness, shaking, mood swings or fatigue. Additionally, the weight loss caused by Mounjaro may mean your body has a lower alcohol tolerance than it did before. The health professionals warned: "Due to the fact that both alcohol and Mounjaro have similar side effects, we recommend that if you are taking Mounjaro, it is best to avoid alcohol, especially after a dose increase or if you already get side effects, however manageable." Drinking can also increase your hunger and weaken your willpower when choosing what to eat. This means you're more prone to consuming additional calories and reversing your weight loss achievements as a result. Cocktails are notorious for being calorie-laden traps, with the classic Piña Colada leading the pack at a staggering 320 calories and 58g of sugar per serving. According to ZAVA's research, the ever-popular Margarita comes in second place with 248 calories, closely followed by the Espresso Martini at 225 calories - though the latter's creamy base also contributes a significant amount of fat. These are often referred to as 'empty calories' due to their lack of nutritional benefits. As a result, they're converted into fat and stored away, leading to weight gain over time. But it's not just alcohol that dieters need to be wary of. The experts pointed out that popular summer drinks labelled as "healthy" rather than "low-fat" or "sugar-free" may not live up to their health claims. They warned: "Drinks can be marketed as 'healthy' or 'refreshing' without delivering on any promises. If you're looking for healthier options, it's best to opt for beverages that clearly state their low sugar and calorie content. "The main health implications of these sugary beverages are that their calories and sugar content go unnoticed. "The high levels of sugar can lead to our blood sugar levels spiking, followed by crashes of fatigue and increased cravings. "These crashes trick our brains into thinking that we need more sugar to feel energised again, although our bodies have already consumed a substantial amount of calories and sugar from one drink alone." Those who've recently begun taking Mounjaro might discover they're naturally less tempted to grab a pint anyway. New research suggests that Mounjaro could potentially reduce cravings for booze. The small-scale study looked at 962 people taking tirzepatide, with more than 70% reporting a diminished desire to drink alcohol. Additional research is needed to confirm these results.
Yahoo
5 days ago
- Business
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Daily Mirror
5 days ago
- Health
- Daily Mirror
People on Mounjaro urged to avoid popular summer drinks as it could ‘make you hungrier'
Drinking alcohol while on Mounjaro could have a range of side effects that may even render your weight loss attempts futile Those taking Mounjaro for weight loss might want to think twice before ordering that cocktail during their summer holidays. Whilst booze doesn't directly clash with the medication, your go-to sugary drink could sabotage your weight loss efforts and trigger side effects that'll put a dampener on your getaway before it's even properly started. Alcohol can send your blood sugar plummeting whilst simultaneously leaving you parched, which amplifies any low blood sugar symptoms you might experience according to experts at ZAVA. This becomes even more pronounced for Mounjaro users, potentially causing dizziness, trembling, irritability or exhaustion. Shedding pounds on Mounjaro may also mean your tolerance for alcohol is reduced. Medical experts cautioned: "Due to the fact that both alcohol and Mounjaro have similar side effects, we recommend that if you are taking Mounjaro, it is best to avoid alcohol, especially after a dose increase or if you already get side effects, however manageable." Alcohol can also ramp up your appetite and weaken your resolve when it comes to making sensible food choices. This means you're more likely to consume extra calories and undo your weight loss progress as a consequence. Cocktails are particularly sneaky calorie bombs, with the humble Piña Colada topping the charts at a whopping 320 calories and 58g of sugar per glass. Coming in second place according to ZAVA's findings is the timeless Margarita containing 248 calories, followed by the Espresso Martini at 225 calories - though the creamy foundation of the latter packs in additional high-fat content. These are dubbed 'empty calories' because they offer zero nutritional value. This results in them being transformed into fat and stored away, causing weight gain as time goes on. However, it's not solely alcohol you need to watch out for if you're determined to stay on your weight loss journey. The specialists highlighted that popular summer beverages bearing vague labels such as "healthy" rather than "low-fat" or "sugar-free" may fail to live up to their claims. They said: "Beverages can be marketed as 'healthy' or 'refreshing' without acting on any promises. If you want to drink healthy beverages, it's best to look for packaging that specifies its low sugar and calorific values. "The main health implications of these sugary beverages are that their calories and sugar content go unnoticed. The high levels of sugar can lead to our blood sugar levels spiking, followed by crashes of fatigue and increased cravings. These crashes trick our brains into thinking that we need more sugar to feel energised again, although our bodies have already consumed a substantial amount of calories and sugar from one drink alone." If you've recently started taking the weight loss drug Mounjaro and find yourself less inclined to reach for a pint in the first place, you're not alone. A recent study has suggested that Mounjaro could potentially curb the desire for alcohol. The limited study examined 962 individuals on tirzepatide, with over 70% reporting a decreased urge to consume alcohol. However, further research is required to substantiate these findings.
Yahoo
28-07-2025
- Business
- Yahoo
Hims & Hers (HIMS) Jumps 14.4% W/W Ahead of Q2 Earnings
We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of the biggest performers recently. Telehealth giant Hims & Hers saw its share prices increase by 14.4 percent week-on-week, from $50.38 to $57.65 on Friday, as investors began repositioning portfolios ahead of its earnings results while taking path from an investment firm's bullish rating for its stock. According to the company, it is scheduled to announce the results of its second quarter earnings performance after market close next Monday, August 4. Last week, Hims & Hers Health, Inc. (NYSE:HIMS) earned a 'strong buy' recommendation from Zacks Research on expectations that its 2025 earnings per share will improve by 177.8 percent year-on-year. Zacks also underscored Hims & Hers Health, Inc.'s (NYSE:HIMS) expansion program with the recent acquisition of ZAVA, a European digital health platform operating in the UK, Germany, France, and Ireland. 'This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA's in-house medical team,' Zacks noted. Pixabay/Public domain 'The integration of ZAVA's technology with Hims & Hers' established brand positions it to deliver personalized, seamless digital healthcare across key European markets,' it added. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
Yahoo
24-07-2025
- Business
- Yahoo
Hims & Hers (HIMS) Soars 16% on Bullish Analyst Outlook
We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of the biggest performers on Wednesday. Hims & Hers rallied for a second day on Wednesday, adding 16.02 percent to close at $58.02 apiece as investors took path from an investment firm's bullish outlook and rating for the company. In a market note on Wednesday, Zacks Research gave Hims & Hers Health, Inc. (NYSE:HIMS) a 'strong buy' recommendation on expectations that its 2025 earnings per share will improve by 177.8 percent year-on-year. Zacks also underscored Hims & Hers Health, Inc.'s (NYSE:HIMS) expansion program with the recent acquisition of ZAVA, a European digital health platform operating in the UK, Germany, France, and Ireland. 'This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA's in-house medical team,' Zacks noted. 'The integration of ZAVA's technology with Hims & Hers' established brand positions it to deliver personalized, seamless digital healthcare across key European markets,' it added. Pixabay/Public Domain According to Hims & Hers Health, Inc. (NYSE:HIMS), it is scheduled to announce the results of its April-June earnings performance after market close on August 4. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
